SCHEMBL2400262

SCHEMBL2400262

COc1ccc(CN(C2CCN2C2=CC(=O)c3sc(C)nc3C2=O)C2CCN2C2=CC(=O)c3sc(C)nc3C2=O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 9/20 0.47
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
THRB P10828 1/20 0.36
CCND1 P24385 1/20 0.36
BLM P54132 1/20 0.36
KMT5A Q9NQR1 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CDC25A P30304 1/20 0.36
CDC25B P30305 1/20 0.36
CDC25C P30307 1/20 0.36
ACHE P22303 2/20 0.35
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
HTR2A P28223 1/20 0.34
APLNR P35414 3/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
USP2 O75604 1/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3813513 0.80 CDC25A (0.45) CDK4MEN1KMT2ATHRBCCND1
SCHEMBL2401288 0.73 CDC25A (0.43) CDK4MEN1KMT2ATHRBCCND1
SCHEMBL2400032 0.71 MAPT (0.46) CDK4MEN1KMT2ATDP1ALDH1A1
SCHEMBL2400259 0.70 CDC25A (0.59) CDK4MEN1KMT2ATHRBCCND1
SCHEMBL2400499 0.68 CDK4 (0.42) CDK4MEN1KMT2ATHRBCCND1
SCHEMBL2399472 0.66 HSD17B10 (0.43) MEN1KMT2ATDP1ALDH1A1KDM4E
SCHEMBL1918214 0.64 TSHR (0.48) CDK4MEN1KMT2AALDH1A1KDM4E
SCHEMBL2403305 0.64 CDK4 (0.61) CDK4MEN1KMT2ATHRBCCND1
SCHEMBL1917577 0.62 CDK4 (0.56) CDK4MEN1KMT2ATHRBCCND1
SCHEMBL11563601 0.58 ALDH1A1 (0.72) MEN1KMT2AALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US claimed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP claimed
US-8017637-B2 Inhibitors of cdc phosphatases IPSEN PHARMA S.A.S. (FR) 2011-09-13 US disclosed
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-11-05 US disclosed
EP-1831209-B1 CDC25 PHOSPHATASE INHIBITORS IPSEN PHARMA (FR) 2009-08-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275624-A1 INHIBITORS OF CDC PHOSPHATASES CDC25C, CDC25A, CDC25B CDK4 72/4885MEN1 1555/4885KMT2A 2264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.